Holen Sie sich die Stockscreener-App
28.69
3.65%
1.01
Handel nachbörslich:
28.69
Schlusskurs vom Vortag:
$27.68
Offen:
$27.69
24-Stunden-Volumen:
269.88K
Relative Volume:
0.43
Marktkapitalisierung:
$1.59B
Einnahmen:
$2.50M
Nettoeinkommen (Verlust:
$-131.12M
KGV:
-10.09
EPS:
-2.8431
Netto-Cashflow:
$-112.73M
1W Leistung:
+1.13%
1M Leistung:
+0.91%
6M Leistung:
-36.72%
1J Leistung:
+70.57%
1-Tages-Spanne:
$27.69
$29.02
1-Wochen-Bereich:
$27.39
$29.54
52-Wochen-Spanne:
$12.81
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
Firmenname
Maze Therapeutics Inc
Sektor
Branche
Telefon
(650) 850-5070
Adresse
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
28.69 | 1.53B | 2.50M | -131.12M | -112.73M | -2.8431 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Eingeleitet | Truist | Buy |
| 2026-03-10 | Eingeleitet | Mizuho | Outperform |
| 2025-12-04 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-14 | Eingeleitet | Raymond James | Outperform |
| 2025-09-02 | Eingeleitet | BTIG Research | Buy |
| 2025-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Maze Therapeutics Inc Aktie (MAZE) Neueste Nachrichten
TradingKey - TradingKey
Maze Therapeutics Inc (MAZE) Institutional Confidence - TradingKey
Maze Therapeutics Inc (MAZE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Maze Therapeutics, Inc. Revenue Breakdown – NASDAQ:MAZE - TradingView
Maze Therapeutics Inc (MAZE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Maze Therapeutics Inc (MAZE) Cash Flow - TradingKey
MAZE|Maze Therapeutics Inc|Price:27.680| - TradingKey
Maze Therapeutics Inc (MAZE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maze Therapeutics Inc (MAZE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Maze Therapeutics Inc (MAZE) Valuation: PE, PB & Fair Value Analysis - TradingKey
BABA: Alibaba Group Holding Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
MAZE|Maze Therapeutics Inc|Price:27.606|Chg%:-0.084 - TradingKey
Maze Therapeutics (MAZE) Investor presentation Summary - Quartr
Maze Therapeutics (MAZE) Corporate presentation Summary - Quartr
Maze Therapeutics (MAZE) Q4 2025 earnings summary - Quartr
Can Maze Therapeutics, Inc. (MAZE) climb 120.48% to reach the level Wall Street analysts expect? - MSN
Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
3 Valuation Signals For Maze Therapeutics (MAZE) As Shares Close At $29.30 - Sahm
Maze Therapeutics (MAZE) Stock Looks Fully Priced After A 59% Gain## - Sahm
Maze Therapeutics Advances MZE782 Phase 2 PKU Trial, Setting Up a New Catalyst for MAZE Investors - TipRanks
MAZE Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock UptickBook Value Growth - dars.gov.et
MAZE Q1 2026 Earnings: Narrower Loss and Clinical Progress Signal MomentumTangible Book Value - dars.gov.et
[Form 4] Maze Therapeutics, Inc. Insider Trading Activity - Stock Titan
Maze Therapeutics (MAZE) CEO’s family trusts sell 34,501 shares under 10b5-1 plan - Stock Titan
Enterprise value to EBITDA forward of Maze Therapeutics, Inc. – NASDAQ:MAZE - TradingView
Form 144 Maze Therapeutics For: 1 July By Investing.com - Investing.com UK
Form 4 Maze Therapeutics Inc For: 1 July By Investing.com - Investing.com Nigeria
MAZE (NASDAQ: MAZE) sale notice: 46,892 shares via option exercise - Stock Titan
Maze Therapeutics CSBO Atul Dandekar sells $210,150 in shares - Investing.com
Maze Therapeutics CSBO Atul Dandekar sells $210,150 in shares By Investing.com - Investing.com South Africa
Maze Therapeutics (MAZE) CSBO sells 7,500 shares under Rule 10b5-1 plan - Stock Titan
MAZE (MAZE) trusts sell tens of thousands of common shares May–June 2026 - Stock Titan
Maze Therapeutics (MAZE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
MAZE Q1 2026 Earnings: Narrower-than-expected loss drives positive stock reactionQuarterly Earnings - dars.gov.et
Enterprise value to revenue forward of Maze Therapeutics, Inc. – NASDAQ:MAZE - TradingView
Maze Therapeutics (MAZE) Gains 2.18% as Shares Test Key Resistance at $30.5Volatility Stop - dars.gov.et
Price to book forward of Maze Therapeutics, Inc. – BOATS:MAZE - TradingView
Enterprise value to EBIT forward of Maze Therapeutics, Inc. – BOATS:MAZE - TradingView
Price to sales forward of Maze Therapeutics, Inc. – BOATS:MAZE - TradingView
Price to earnings forward of Maze Therapeutics, Inc. – NASDAQ:MAZE - TradingView
Enterprise value to revenue forward of Maze Therapeutics, Inc. – BOATS:MAZE - TradingView
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors? - Yahoo Finance
Maze Therapeutics (MAZE) Rebounds This Week, Is The Upside Already Priced In? - Sahm
MAZE Forecast — Price Target — Prediction for 2027 - TradingView
GHRS Stock Price and Chart — NASDAQ:GHRS - TradingView
Maze Therapeutics, Inc. Actuals & Estimates (NASDAQ:MAZE) - TradingView
Maze Therapeutics (MAZE) CEO sells 27,858 shares under 10b5-1 trading plan - Stock Titan
MAZE Q1 2026 Earnings: Narrower Loss as EPS Beats Estimates by 19.14%Earnings Expansion Phase - dars.gov.et
Mizuho Securities Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $97 - Moomoo
Analyst Reaffirms Buy on Maze with Unchanged $110 Price Target, Citing Strong HORIZON Data and Favorable Risk-Reward - TipRanks
H.C. Wainwright Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $110 - Moomoo
Finanzdaten der Maze Therapeutics Inc-Aktie (MAZE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):